Cepton, Inc. (NASDAQ:CPTN – Get Free Report) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 63,100 shares, a drop of 8.0% from the August 31st total of 68,600 shares. Based on an average daily volume of 47,800 shares, the days-to-cover ratio is currently 1.3 days. Approximately 1.0% of the shares of the company are sold short.
Analysts Set New Price Targets
Separately, Westpark Capital reissued a “hold” rating on shares of Cepton in a research report on Wednesday, August 14th.
Check Out Our Latest Report on CPTN
Cepton Stock Performance
Cepton (NASDAQ:CPTN – Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.26. The firm had revenue of $10.43 million for the quarter, compared to analyst estimates of $11.00 million.
About Cepton
Cepton, Inc provides lidar-based solutions for automotive, smart cities, smart spaces, and smart industrial applications in the United States, Japan, China, and internationally. The company offers autograde lidar sensors, including Cepton Ultra, a slimmest lidar with MagnoSteer technology and proprietary ASIC chipset, enabling a combination of 300-meter range at 10% reflectivity and 0.05° resolution; Vista-X, a compact lidar solution with a range of up to 200m for long-range applications in ADAS L2+/L3, AV L4/L5, and suitable for smart infrastructure applications; and Nova, an extremely-small form factor lidar solution with a range of up to 30m for near-range applications in ADAS L2+/L3, AV L4/L5, and suitable for smart infrastructure applications.
Recommended Stories
- Five stocks we like better than Cepton
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Retail Stocks Investing, Explained
- 2 Energy Stocks Fueling the AI Datacenter Boom
- How to Use Stock Screeners to Find Stocks
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Cepton Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepton and related companies with MarketBeat.com's FREE daily email newsletter.